Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...

Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...

Innovation is urgent and direly needed as pediatric cancers remain the leading disease-based cause of pediatric death in the United States. OS Therapies is empowered to continue its groundbreaking ...

February 17, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today provided a global regulatory update for ...

OS Therapies’ cancer vaccine, OST-HER2, has been shown to significantly improve overall survival (OS) in patients with recurrent, fully resected, pulmonary metastatic osteosarcoma after two years.

According to DelveInsight's analysis, the market size for osteosarcoma in the 7MM is expected to grow significantly by 2034. As per DelveInsight estimates, the total incident population of ...

While genetic sequencing has previously helped to uncover different subtypes of other cancers, like breast or skin cancer, for which those patients then receive targeted treatment personalised to ...

Osteosarcoma is a malignant neoplasm of the bone and is the most common histological form of primary bone cancer. It is most prevalent in children and young adults, as it is associated with the ...

The histopathological features of osteosarcoma vary widely, often leading to diagnostic difficulties particularly when there is little evidence of osteoid formation. The report describes the ...

Only 17 years young, Jayden Bailey lost his battle with cancer on Thursday, Lebanon High School Head Basketball Coach Jim ...